JP2018514565A5 - - Google Patents

Download PDF

Info

Publication number
JP2018514565A5
JP2018514565A5 JP2017556902A JP2017556902A JP2018514565A5 JP 2018514565 A5 JP2018514565 A5 JP 2018514565A5 JP 2017556902 A JP2017556902 A JP 2017556902A JP 2017556902 A JP2017556902 A JP 2017556902A JP 2018514565 A5 JP2018514565 A5 JP 2018514565A5
Authority
JP
Japan
Prior art keywords
depot
vaccine
seq
forming
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017556902A
Other languages
English (en)
Japanese (ja)
Other versions
JP6851983B2 (ja
JP2018514565A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2016/050487 external-priority patent/WO2016176761A1/en
Publication of JP2018514565A publication Critical patent/JP2018514565A/ja
Publication of JP2018514565A5 publication Critical patent/JP2018514565A5/ja
Application granted granted Critical
Publication of JP6851983B2 publication Critical patent/JP6851983B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017556902A 2015-05-01 2016-04-27 デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法 Expired - Fee Related JP6851983B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155677P 2015-05-01 2015-05-01
US62/155,677 2015-05-01
PCT/CA2016/050487 WO2016176761A1 (en) 2015-05-01 2016-04-27 Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines

Publications (3)

Publication Number Publication Date
JP2018514565A JP2018514565A (ja) 2018-06-07
JP2018514565A5 true JP2018514565A5 (https=) 2019-05-23
JP6851983B2 JP6851983B2 (ja) 2021-03-31

Family

ID=57217405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556902A Expired - Fee Related JP6851983B2 (ja) 2015-05-01 2016-04-27 デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法

Country Status (4)

Country Link
US (1) US20180162913A1 (https=)
EP (1) EP3288538A4 (https=)
JP (1) JP6851983B2 (https=)
WO (1) WO2016176761A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509384A (ja) 2015-01-06 2018-04-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リピドａ模倣体、調製方法、及びその使用
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
US11260116B2 (en) 2016-05-04 2022-03-01 Immunovaccine Technologies Inc. Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
JP7125197B2 (ja) 2016-09-27 2022-08-24 イミューノヴァクシーン テクノロジーズ インコーポレイテッド ヒト対象において抗体免疫応答を誘導するために低投与体積ｂ細胞エピトープ組成物を使用する方法
WO2018151816A1 (en) * 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
CN109456405B (zh) * 2017-09-06 2022-02-08 上海交通大学医学院附属仁济医院 一种去棕榈酰化pd-l1蛋白质及其制备方法和应用
CN111565706A (zh) * 2017-11-09 2020-08-21 免疫疫苗技术公司 药物组合物、包括脂质囊泡颗粒尺寸设定的制备方法及其用途
CN107988373A (zh) * 2018-01-10 2018-05-04 上海交通大学医学院附属仁济医院 用于预测癌症免疫治疗效果的生物标志物、试剂盒与应用
WO2019178677A1 (en) * 2018-03-20 2019-09-26 Immunovaccine Technologies Inc. Methods and compositions for targeted delivery of active agents and immunomodulatory agents to lymph nodes
KR20210086612A (ko) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 펩타이드 백신
US20220125903A1 (en) * 2018-11-19 2022-04-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
WO2024186646A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making lipid adjuvanted compositions
WO2024186623A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making dried pharmaceutical compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
JP4516916B2 (ja) * 2003-07-11 2010-08-04 昇志 佐藤 リビン由来のｈｌａ−ａ２４結合性癌抗原ペプチド
US7749520B2 (en) * 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
JP2008532929A (ja) * 2005-02-01 2008-08-21 メディバス エルエルシー ワクチン送達組成物および使用法
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US7947286B2 (en) * 2005-10-07 2011-05-24 Panthera Biopharma Llc Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
WO2009025770A2 (en) * 2007-08-17 2009-02-26 Wyeth A heterologous prime-boost immunization regimen
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
ES2524699T3 (es) * 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
EP2552490A4 (en) * 2010-03-26 2013-12-18 Emergent Product Dev Gaithersburg Inc INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
WO2014055289A1 (en) * 2012-10-01 2014-04-10 Thomas Jefferson University Immunization with rabies virus vector expressing foreign protein antigen
US10022441B2 (en) * 2013-03-27 2018-07-17 Immunovaccine Technologies, Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2018514565A5 (https=)
Yang et al. Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases
Moni et al. Advancements in vaccine adjuvants: the journey from alum to nano formulations
Gote et al. A comprehensive review of mRNA vaccines
Facciolà et al. An overview of vaccine adjuvants: current evidence and future perspectives
Filipić et al. Nanoparticle-based adjuvants and delivery systems for modern vaccines
Tan et al. Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants
Kaurav et al. Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage
Tornesello et al. Nanoparticles to improve the efficacy of peptide-based cancer vaccines
TWI672149B (zh) 改良之疫苗組成物及使用方法
Gomes et al. Harnessing nanoparticles for immunomodulation and vaccines
Cunningham et al. Vaccine development: From concept to early clinical testing
JP2015522580A5 (https=)
Martiñón et al. Chemical and immunological characteristics of aluminum‐based, oil‐water emulsion, and bacterial‐origin adjuvants
Barnier-Quer et al. Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators
Alving et al. Adjuvants for human vaccines
Jabbal-Gill Nasal vaccine innovation
JP2014520807A5 (https=)
Levast et al. Vaccine potentiation by combination adjuvants
JP2018534304A5 (https=)
Goetz et al. Vaccine adjuvants for infectious disease in the clinic
Atmar et al. Adjuvants for pandemic influenza vaccines
Dowling et al. Pediatric vaccine adjuvants: components of the modern vaccinologist’s toolbox
JP2014522842A5 (https=)
CN103768595B (zh) 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗